Question 1 (5 points)
Saved
GLP-1 agonists:
Question 1 options:
Directly bind to a receptor in the pancreatic beta cell
Can be given orally once daily
Have been approved for monotherapy
Speed gastric emptying to decrease appetite
Question 2 (5 points)
Saved
Potentially fatal granulocytopenia has been associated with treatment of hyperthyroidism with
propylthiouracil. Patients should be taught to report:
Question 2 options:
Hypocalcemia and osteoporosis
Tinnitus and decreased salivation
Fever and sore throat
Laryngeal edema and difficulty swallowing
Question 3 (5 points)
Saved
When starting a patient on levothyroxine for hypothyroidism the patient will need follow-up
measurement of thyroid function in:
Question 3 options:
Two months
Four weeks
Two weeks
Six months
Question 4 (5 points)
Saved
After starting a patient with Grave's disease on an antithyroid agent such as methimazole, initial
patient monitoring includes thyroid-stimulating hormone (TSH) and free thyroxine (T4) every:
Question 4 options:
1 to 2 weeks
3 to 4 weeks
, 2 to 3 months
6 to 9 months
Question 5 (5 points)
Saved
Sulfonylureas may be added to a treatment regimen for type 2 diabetics when lifestyle
modifications and metformin are insufficient to achieve target glucose levels. Sulfonylureas have
been moved to step 2 therapy because they:
Question 5 options:
Increase endogenous insulin secretion
Address the insulin resistance found in type 2 diabetics
Increase the risk for hypoglycemia
Improve insulin binding to receptors
Question 6 (5 points)
Saved
The decision may be made to switch from twice daily NPH insulin to insulin glargine to improve
glycemia control throughout the day. If this is done:
Question 6 options:
Patients who have been on high doses of NPH will need tests for
insulin antibodies.
The initial dose of glargine is 2 to 10 units per day.
Obese patients may require more than 100 units per day.
The initial dose of glargine is reduced by 20% to avoid
hypoglycemia.
Question 7 (5 points)
Saved
Metformin is a primary choice of drug to treat hyperglycemia in type 2 diabetes because it:
Question 7 options:
Decreases peripheral glucose utilization
Decreases glycogenolysis by the liver
Substitutes for insulin usually secreted by the pancreas
Increases the release of insulin from beta cells
Question 8 (5 points)
Saved
GLP-1 agonists:
Question 1 options:
Directly bind to a receptor in the pancreatic beta cell
Can be given orally once daily
Have been approved for monotherapy
Speed gastric emptying to decrease appetite
Question 2 (5 points)
Saved
Potentially fatal granulocytopenia has been associated with treatment of hyperthyroidism with
propylthiouracil. Patients should be taught to report:
Question 2 options:
Hypocalcemia and osteoporosis
Tinnitus and decreased salivation
Fever and sore throat
Laryngeal edema and difficulty swallowing
Question 3 (5 points)
Saved
When starting a patient on levothyroxine for hypothyroidism the patient will need follow-up
measurement of thyroid function in:
Question 3 options:
Two months
Four weeks
Two weeks
Six months
Question 4 (5 points)
Saved
After starting a patient with Grave's disease on an antithyroid agent such as methimazole, initial
patient monitoring includes thyroid-stimulating hormone (TSH) and free thyroxine (T4) every:
Question 4 options:
1 to 2 weeks
3 to 4 weeks
, 2 to 3 months
6 to 9 months
Question 5 (5 points)
Saved
Sulfonylureas may be added to a treatment regimen for type 2 diabetics when lifestyle
modifications and metformin are insufficient to achieve target glucose levels. Sulfonylureas have
been moved to step 2 therapy because they:
Question 5 options:
Increase endogenous insulin secretion
Address the insulin resistance found in type 2 diabetics
Increase the risk for hypoglycemia
Improve insulin binding to receptors
Question 6 (5 points)
Saved
The decision may be made to switch from twice daily NPH insulin to insulin glargine to improve
glycemia control throughout the day. If this is done:
Question 6 options:
Patients who have been on high doses of NPH will need tests for
insulin antibodies.
The initial dose of glargine is 2 to 10 units per day.
Obese patients may require more than 100 units per day.
The initial dose of glargine is reduced by 20% to avoid
hypoglycemia.
Question 7 (5 points)
Saved
Metformin is a primary choice of drug to treat hyperglycemia in type 2 diabetes because it:
Question 7 options:
Decreases peripheral glucose utilization
Decreases glycogenolysis by the liver
Substitutes for insulin usually secreted by the pancreas
Increases the release of insulin from beta cells
Question 8 (5 points)
